Market watch: Strategies for biosimilars in emerging markets

Nature Reviews Drug Discovery 16, 520 (2017). doi:10.1038/nrd.2017.113 Author: Ajay Gautam Biologic drugs remain inaccessible to most patients in emerging markets. Biosimilars represent a compelling proposition for patient affordability and access, and attractive value for governments in many of these countries. However, quality concerns, technology hurdles, lack of robust regulatory frameworks, and development timelines and costs
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research